Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of.

Published On Nov 15, 2024, 9:43 AM

Analysts are suggesting that Wall Street's response to Robert F. Kennedy Jr.'s nomination to lead the U.S. Health and Human Services is exaggerated. Vaccine and pharmaceutical stocks dropped significantly following the announcement, as Kennedy is known for his skepticism towards vaccines and the drug approval process. However, analysts believe that the overall market reaction does not accurately reflect the potential impact of his appointment, pointing out that Kennedy has not proposed drastic changes to healthcare policies. Expected volatility in the sector is seen as more of a sentiment issue rather than a reflection of solid policy threats.

Read full article

Stock Forecasts

PFEView PFE chart on TradingView

Positive

Given the overreaction in the market, and with analysts suggesting that the actual impact of Kennedy's policies may be less drastic than feared, there could be an opportunity to buy some of the biotech and pharma stocks currently under pressure.

MRNAView MRNA chart on TradingView

Positive

Despite the concerns regarding RFK Jr.'s stance on vaccines potentially affecting sentiment in the market, analysts indicate that the negative trends in stock prices may not be justified long-term.

GSKView GSK chart on TradingView

Positive

Investors may want to consider the rebounds in the pharma and biotech sector due to an exaggerated reaction to political news. As the dust settles, these stocks may recover.

Related News

Stock market today: Dow, S&P 500, Nasdaq slide as traders trim rate-cut bets

Nov 15, 2024, 10:16 AM

Wall Street is absorbing a jump in retail sales and Jerome Powell's hawkish comments as Trump-fueled optimism starts to wear off.

XLK
XLY
MRNA

Robert F. Kennedy Jr.’s Billion-Dollar Hit to Big Pharma

Nov 15, 2024, 8:09 AM

Donald Trump’s choice to run the Department of Health and Human Services spooked investors who worry what Kennedy would do.

PFE
MRNA

New York Times Takes European Commission to Court Over Covid Vaccine Deal

Nov 15, 2024, 5:25 AM

The news outlet is pushing the Commission to release text messages between the E.U.’s top official and Pfizer as they negotiated a vaccine contract.

PFE